# Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis

> **NCT01265602** · PHASE3 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 889 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** LAS41007
- **DRUG:** LASW1510
- **DRUG:** vehicle of LAS41007

## Key facts

- **NCT ID:** NCT01265602
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 889 (ACTUAL)
- **Last updated:** 2012-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265602, "Double-blind, Randomized, Vehicle- and Comparator-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of LAS41007 in the Treatment of Actinic Keratosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01265602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*